The long-term objective of this project is to determine the function(s) of dystrophin in striated muscle in order to understand how its absence or abnormality leads to the pathologies observed in Duchenne (DMD) and Becker (BMD) muscular dystrophies. During the most recent project period, we uniquely employed the baculovirus expression system and an array of biochemical/biophysical assays to define the actin binding properties of dystrophin and its homologue utrophin. We also demonstrated that dystrophin functions to organize the microtubule lattice of skeletal muscle through a direct binding interaction. Finally, we demonstrated that a baculovirus-expressed TAT-micro-utrophin construct shows promise as a novel protein replacement therapy for DMD. Based on these published results and exciting new preliminary data, we propose three new specific aims to: 1) test the hypothesis that disease-causing missense mutations in dystrophin cause a loss of function through protein aggregation, 2) determine the functional importance of microtubule lattice organization in skeletal muscle, and 3) reinvestigate functional necessity for the dystrophin carboxyl-terminal domain in skeletal muscle. The project will employ biochemical/biophysical methods to characterize a variety of dystrophin and utrophin protein constructs in combination with complementary experiments in isolated cells and transgenic mice. The proposed studies will address several fundamental questions about the function of dystrophin in normal skeletal muscle and how its absence or abnormality causes human diseases of skeletal muscle.

Public Health Relevance

Duchenne muscular dystrophy (DMD) afflicts 1 in 3,500 live-born males and is typically lethal by the third decade. No effective therapies are currently available for DMD. Dystrophin is the protein missing in patients with DMD, but its function in muscle is not fully understood. Through rigorous biochemical/biophysical characterization of full-length dystrophin and utrophin in combination with complementary experiments in isolated cells and transgenic mice, the proposed studies will elucidate the functions of dystrophin in normal muscle and how its absence causes muscular dystrophy. Thus, this project is highly relevant to understanding the pathological mechanism of Duchenne muscular dystrophy and for the development of effective therapies.

Agency
National Institute of Health (NIH)
Institute
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Type
Research Project (R01)
Project #
5R01AR042423-19
Application #
8499256
Study Section
Skeletal Muscle and Exercise Physiology Study Section (SMEP)
Program Officer
Nuckolls, Glen H
Project Start
1994-07-15
Project End
2015-06-30
Budget Start
2013-07-01
Budget End
2014-06-30
Support Year
19
Fiscal Year
2013
Total Cost
$335,220
Indirect Cost
$105,211
Name
University of Minnesota Twin Cities
Department
Biochemistry
Type
Schools of Medicine
DUNS #
555917996
City
Minneapolis
State
MN
Country
United States
Zip Code
55455
Lindsay, Angus; McCourt, Preston M; Karachunski, Peter et al. (2018) Xanthine oxidase is hyper-active in Duchenne muscular dystrophy. Free Radic Biol Med 129:364-371
Strakova, Jana; Kamdar, Forum; Kulhanek, Debra et al. (2018) Integrative effects of dystrophin loss on metabolic function of the mdx mouse. Sci Rep 8:13624
Le, Shimin; Yu, Miao; Hovan, Ladislav et al. (2018) Dystrophin As a Molecular Shock Absorber. ACS Nano :
McCourt, Jackie L; Talsness, Dana M; Lindsay, Angus et al. (2018) Mouse models of two missense mutations in actin-binding domain 1 of dystrophin associated with Duchenne or Becker muscular dystrophy. Hum Mol Genet 27:451-462
Nelson, D'anna M; Lindsay, Angus; Judge, Luke M et al. (2018) Variable rescue of microtubule and physiological phenotypes in mdx muscle expressing different miniaturized dystrophins. Hum Mol Genet 27:2090-2100
Lindsay, Angus; Schmiechen, Alexandra; Chamberlain, Christopher M et al. (2018) Neopterin/7,8-dihydroneopterin is elevated in Duchenne muscular dystrophy patients and protects mdx skeletal muscle function. Exp Physiol 103:995-1009
Belanto, Joseph J; Olthoff, John T; Mader, Tara L et al. (2016) Independent variability of microtubule perturbations associated with dystrophinopathy. Hum Mol Genet 25:4951-4961
McCourt, Jackie L; Rhett, Katrina K; Jaeger, Michele A et al. (2015) In vitro stability of therapeutically relevant, internally truncated dystrophins. Skelet Muscle 5:13
Talsness, Dana M; Belanto, Joseph J; Ervasti, James M (2015) Disease-proportional proteasomal degradation of missense dystrophins. Proc Natl Acad Sci U S A 112:12414-9
Filareto, Antonio; Rinaldi, Fabrizio; Arpke, Robert W et al. (2015) Pax3-induced expansion enables the genetic correction of dystrophic satellite cells. Skelet Muscle 5:36

Showing the most recent 10 out of 42 publications